Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Launched by AB SCIENCE · Oct 10, 2011

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients aged 18 to 60 years, from both sex, and suffering from multiple sclerosis either primary progressive or secondary progressive without relapse within 2 years before inclusion.
• • 2. Patients with EDSS score in the range of 2 to 6.5, inclusive
• • 3. EDSS progression ≥ 1 point within 2 years before inclusion
• Exclusion Criteria:
• • 1. Disease other than MS responsible for clinical signs and/or MRI lesions
• • 2. Secondary progressive MS with relapse in the 2 years before inclusion
• • 3. Treatment with interferon or glatiramer acetate within four weeks prior to treatment allocation
• • 4. Treatment with oral or systemic corticosteroids or ACTH within four weeks prior to treatment allocation.
• • 5. Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection